Nasdaq

Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
Nasdaq

Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
Reuters

Axonics Reports FDA Approval Of Wireless Patient Remote Control With SmartMRI Technology

* AXONICS MODULATION TECHNOLOGIES - FDA REVIEW OF LABELING EXPANSION EXPECTED TO COMPLETE IN EARLY Q4 Source text for Eikon: Further company coverage: ...
MD&M East

Axonics Closes a Portfolio Gap in Sacral Neuromodulation

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
MD&M East

Axonics R20 Rechargeable Sacral Neuromodulation System Nabs CE Mark

Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...